FTSE 100 news / Companies and sectors / AstraZeneca / 10 October 2026
AstraZeneca (AZN): news on Saturday 10 October 2026
+2.0 slightly positive
Coverage centred on the Summit Therapeutics investment and a CE mark for a companion diagnostic tied to AstraZeneca's breast cancer drug. Shares were reported edging lower and a price forecast flagged support under pressure, which tempers the positive pipeline news.
What drove it
- Summit Therapeutics investment
- camizestrant diagnostic approval
- share price moves
The 9 stories
- +7.5 Guardant Health Assay Nabs CE Mark as CDx for AstraZeneca’s Etcamah in Breast Cancer
CE mark for diagnostic paired with AstraZeneca's breast cancer drug. - +7.5 Guardant360 CDx Gains CE Mark as Camizestrant Companion Diagnostic
Companion diagnostic CE mark supports camizestrant, AstraZeneca's drug. - +5.8 AstraZeneca CEO Highlights Summit Drug’s Potential in Cancer Treatment
CEO highlights potential of Summit cancer drug, linked to AstraZeneca investment. - −4.2 AstraZeneca stock price prediction: GBX11,694 support under pressure
Share price support level said to be under pressure. - −3.3 Why Are AstraZeneca (LSE:AZN) Shares Edging Lower After The Summit Therapeutics Investment Today?
Shares edging lower after Summit Therapeutics investment. - −2.5 ‘Burn in hell’: Fired scientist’s death threats against AstraZeneca, Aetna officials land him in prison, but diatribes continue
Death threats against AstraZeneca officials; company a named victim. - +1.7 Key facts: Tempus AI (TEM) Q2 $382.5M; Oncology Model for AstraZeneca
Tempus oncology model for AstraZeneca, mildly positive collaboration. - +1.7 AstraZeneca stock gains 0.66 percent after-hours to EUR 142.53
Small after-hours share price gain. - 0.0 AstraZeneca stock trades at EUR 142.88 with 362,423 shares versus 3,369,364 average
Routine trading volume and price update.
AstraZeneca: every day · Pharma and healthcare on 10 October 2026 · FTSE 100 overview for the day